Study to obtain data about changing from the chlorofluorocarbon (CFC) - containing Berotec® 200 µg metered - dose inhaler to the CFC - free Berotec® N 100 µg metered - dose inhaler
Study Type
OBSERVATIONAL
Enrollment
2,914
Change in the clinical picture of chronic obstructive airways disease on switching from Berotec® 200 µg to Berotec® N 100 µg
Time frame: After 3 weeks of first drug administration
Investigator assessment of efficacy on a 4-point scale
Time frame: Up to 3 weeks after first drug administration
Patient assessment of efficacy on a 4-point scale
Time frame: Up to 3 weeks after first drug administration
Patient assessment of tolerability on a 4-point scale
Time frame: Up to 3 weeks after first drug administration
Investigator comparative overall assessment on a 4-point scale
Time frame: After 3 weeks of first drug administration
Number of patients with adverse drug reactions
Time frame: Up to 3 weeks after first drug administration
Number of patients who changed the concomitant medication
Time frame: Up to 3 weeks after first drug administration
Number of patients who continued treatment
Time frame: Up to 3 weeks after first drug administration
Number of patients who premature withdrew from the treatment
Time frame: Up to 3 weeks after first drug administration
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.